PF-Atlas › Clinical Trials › NCT02789397

Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency

Rituximab and Azathioprine · Phase 2

Registry ID
NCT02789397
Phase
Phase 2
Status
Withdrawn
Drug / intervention
Rituximab (RTX) and Azathioprine (AZA)
Sponsor
Medical College of Wisconsin
Start
2016-05-02

About this trial

This phase II study will assess the effect of a treatment combination of Rituximab and azathioprine in patients with Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) compared to placebo, based on change in lung function at 18 months compared to baseline. The researchers will also assess if the drugs improved quality of life.

View NCT02789397 on ClinicalTrials.gov →

Explore related

All Rituximab and Azathioprine trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT02789397 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.